Argenx debuts first DTC for myasthenia gravis med Vyvgart even as MG community effort continues
In a quick turn to DTC, argenx is rolling out its first campaign for myasthenia gravis med Vyvgart just a month after FDA approval. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
